Source: Global Network
According to the " United News Network ", it was reported recently that the Taiwan epidemic command center is actively negotiating for Moderna vaccine OEM. Taiwan's "National Health Center" prepares for the "Vaccine Factory 2" and also hopes to sign a mass production authorization with Moderna. Everything seems to be going smoothly, but former "Disease Control Director" Su Yiren said, "This is a fantasy." Last year, the DPP authorities called for self-producing masks, but the technical barriers of masks are extremely low. The mRNA (messenger ribonucleic acid) vaccine technology is difficult. According to Taiwan's existing technology and capacity, it is like a big cake in the air, and it feels just a shout-out.
"United News Network" report screenshot
Su Yiren said that every vaccine factory has a fixed vaccine production line, and these listed companies must give up their original production lines and change them to mRNA vaccines. He said: It is only possible unless all of them are taken back and integrated by the Taiwan authorities.
Taiwan's epidemic command center actively negotiates on Moderna's vaccine OEM. Su Yiren, the former "Disease Control Director" believes that this is a fantasy. Photo from "United News Network"
report that Su Yiren pointed out two major problems. Taiwan has never developed an mRNA vaccine, and the front-end production technology is equal to a blank. In addition, the vaccine energy is insufficient. There are reports that the DPP authorities want to "produce 300 million to 500 million doses of Moderna vaccine in six to nine months." This bull is too loud. When an insider hears it, he knows that this is impossible.
Former "Disease Control Director" Su Yiren. Photo from "TVBS News Network "
Su Yiren said that mRNA vaccine is a brand new technology, and it may be okay to cultivate a small amount of cells, but it is quite difficult to cultivate from five milliliters to fifty milliliters. If you want to make a large amount, make raw materials such as 50 milliliters, 100 milliliters, 200 milliliters, and even 500 liters, 200 liters, 200 liters, and 200 liters. The challenge of each level is quite great, "the more the quantity, the higher the difficulty."
report mentioned that Liu Jiaqi, an associate researcher at the Institute of Infectious Diseases and Vaccines at the National Health Hospital, said that how to wrap mRNA into a lipid membrane and send it to the human body is the biggest technical challenge at present. It is Moderna's most powerful technology and the part that Taiwan must learn and learn from. In addition, Taiwan also needs to develop related adjuvants and other systems, and can only manufacture and produce it by itself once the epidemic breaks out. Su Yiren believes that unless Moderna's original factory sends personnel to the "National Health Center" and puts all its technical support, Taiwanese manufacturers will at most fill this part.
reported that production capacity is another major problem. Su Yiren said that as early as April last year, the "Epidemic Prevention Innovation Alliance (CEPI)" that participated in the creation of the COVAX ( COVID-19 Vaccine Implementation Plan) platform sent people to Taiwan to understand the capacity of Taiwan biotech manufacturers OEM vaccines. At that time, it was estimated that at most 10 million doses of the new crown vaccine could be produced in a month. The island's vaccine production capacity is limited, which explains the reason why the command center negotiated with the AstraZeneca vaccine to break the deadlock in August last year.
Su Yiren also mentioned that the three major vaccine factories on the island, including "Guoguang, Lianya, and High-end", are actively developing their own new crown vaccines, and the production lines that can be moved are very limited. As for another manufacturer, "Taikang", the production capacity is not large. The command center wants to gather the strength of many factories on the island to produce 300 million to 500 million doses of mRNA vaccines within six to nine months, which is absolutely impossible.
Su Yiren admitted that "producing mRNA vaccines is by no means a simple matter." Moderna only produced tens of millions of doses at the end of last year. After overcoming many problems, it gradually expanded its production capacity this year. In addition, in addition to political factors, the main factor is that the "Samsung Bio" factory is large enough, but even so, South Korea has only negotiated the cooperation between sterile filling, labeling and packaging in the latter part. It is still unknown whether technology can be transferred. 【Global Network 】
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-